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Etanercept
S Chimenti
Department of Dermatology, University of Rome Tor Vergata, Rome, Italy
Etanercept is a recombinant molecule consisting of the extracellular domain
of the tumor necrosis factor-alpha (TNF-alpha) p75 receptor fused to the inert FC
portion of IgG1 molecule. The dimeric nature of etanercept permits binding
of the protein to two free or receptor bound molecules of TNF-alpha at an affinity
50 to 1000 times that of soluble monomeric forms of the TNF-alpha; receptor. In
contrast with anti-TNF antibodies, etanercept does not induce complement
mediated TNF-alpha cell lysis in vitro. This agent modulates biologic responses
regulated by TNF-alpha a pro-inflammatory cytokine involved in the pathogenesis
of psoriasis. Several studies demonstrated efficacy and tolerability of etanercept
administered twice weekly by subcutaneous injections in patients with moderate to
severe psoriasis and/or psoriatic arthritis refractory to conventional therapies.
Starting from 2003, more than 250 patients were treated in clinical trials
at the Department of Dermatology, University of Rome Tor Vergata, confirming
that etanercept is a highly effective and safe treatment for patients affected by
moderate-to-severe plaque psoriasis and psoriatic arthritis, as it reduces
patients disease activity, increases functional capacity and improves
quality of life. Moreover, the use of a high-dose regimen or long-term therapy
can improve, in selected cases, clinical results. Mean time to relapse following
etanercept withdrawal was observed approximately 4 months after discontinuation,
however, PASI 75 responses were re-obtained after re-treatment. In addition we
observed that etanercept is an effective and well-tolerated agent also for the
treatment of childhood psoriasis and in patients with erythrodermic or pustolar
psoriasis.
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Efficacy and Safety in the Long-Term Treatment with Infliximab of
Psoriasis and Psoriatic Arthritis
M Papoutsaki and S Chimenti
Department of Dermatology, University of Rome ‘‘Tor Vergata’’, Rome, Italy
Effective therapies without significant long-term toxicity are needed for the chronic
course of psoriasis. Infliximab is a a chimeric anti-tumor necrosis factor-alpha
monoclonal IgG1 antibody that binds with high affinity and specificity to TNF-
alpha; and neutralises its biological activity. Currently it is approved for the
treatment of chronic diseases characterised by TNFalpha-mediated inflammation
such as rheumatoid arthritis, Crohn’s disease, ankylosing spondylitis, psoriatic
arthitis and more recently for psoriasis. In recent clinical studies, infliximab was
effective and generally well tolerated in patients with moderate to severe psoriasis
or psoriatic arthritis. We performed an open-label clinical trial with infliximab at
weeks 0, 2 and 6, followed by maintenance every 8 weeks. Evaluations were at
baseline, week 22, at 1 year and at 2 years. Primary efficacy end-points were
475% improvement of PASI (PASI 75) in the plaque-type patients and changes
from baseline in the health assessment questionnaire (HAQ) in the arthropatic
patients. A total number of 163 patients were treated (85 patients affected by
plaque-type psoriasis and 78 patients affected by psoriatic arthritis). At the present
moment, 145 patients have reached the 22nd week of treatment, 97 patients have
reached 1 year of treatment and 50 patients have reached 2 years of treatment.
Results are being discussed. No serious adverse events or delayed hypersensitivity
reactions were noted. Our experience seems to indicate that Infliximab is an
effective and safe therapy for the long-term treatment of psoriasis and may have a
lower incidence of side effects than traditional systemic anti-psoriatic therapies.
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Efalizumab
K Peris and M.C. Fargnoli
Department of Dermatology, University of L’Aquila, L’Aquila, Italy
Psoriasis is a common immune-mediated disease associated with significant
psychosocial morbidity and a decrease in patients health-related quality of life.
Efalizumab is a recombinant humanized, monoclonal IgG1, antibody approved for
the treatment of chronic moderate-to-severe plaque psoriasis. Efalizumab binds to
CD11a, the alpha subunit of LFA-1, inhibiting T-cell activation, cutaneous T-cell
trafficking and adhesion to keratinocytes. Numerous randomized, double-blind,
placebo-controlled trials confirmed the efficacy and safety of 12 weekly doses of
s.c. efalizumab 1.0 mg/kg/wk in patients with moderate-to-severe psoriasis (PASI
Z12 and BSA Z10%). On day 84, 31% of patients who received efalizumab
demonstrated Z 75% improvement in PASI relative to baseline as compared with
4% of placebo-treated patients. In addition, 54% of patients undergoing efalizumab
treatment had 50% PASI improvement as compared with 14% receiving placebo.
In addition, a significant improvement of Overall Lesion Severity, Physician Global
Assessment and patient’s quality of life was observed. Extending treatment from 12
to 24 weeks both maintains and improves the initial response achieved at 12
weeks. Efficacy and safety of long-term efalizumab therapy has been also examined
in a 36 month clinical trial which demonstratedZ75 PASI improvement in 73% of
patients. The most frequent side-effect was a flulike syndrome, which in most cases
was reversible after the 3rd injection. No increased incidence of neoplasia,
infections, arthritis and hematologic disorders have been registered so far. In
conclusion, efalizumab is well-tolerated, safe and allows a long-term treatment,
improving patients’ overall quality of life.
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The use of Biologics in the Treatment of Skin Cancers
L Bianchi
Department of Dermatology, Tor Vergata University of Rome, Rome, Italy
Biologics are a set of different engineered proteins used to modify immune
reactions. Their use in immune-mediate dermatoses has been proposed and
validated because of their effects on defined pathophysiological pathways that
regulate pivotal immunological processes such as lymphocytes activation,
interaction with antigen-presenting cells and endothelial cells and production
and action of cytokines and chemokines. In contrast to general immunosuppres-
sants, they do not affect the entire immune system or have significant end-organ
toxicity. Even though a past positive history for internal as well as cutaneous
neoplasm is considered a specific contraindication to their use and the risk of
opportunistic neoplasm is still matter of debate, some biologics directed to normal
as well as malignant cells are successfully proposed in selected fields of dermato-
oncology. In particular, cutaneous T-cell lymphomas served as a paradigm for the
development of biological agents. In particular, Alemtuzumab, anti-CTLA-4
monoclonal antibody, rituximab, different cytokines (rIFN, rIL-2, immunotoxin
conjugate denileukin diftitox, IL-12), some of them investigational, have been
tested in dermatology. Alemtuzumab, an anti-CD52 humanized monoclonal
antibody, and immunotoxin conjugate denileukin diftitox, have been demonstrated
to be successful in advanced cutaneous T-cell lymphomas (mycosis fungoides/
Sezay syndrome, CD30-negative CD8-positive cytotoxic large T-cell lymphoma,
subcutaneous T-cell lymphoma). Rituximab, a chimeric anti-CD20 monoclonal
antibody, has been demonstrated to be highly effective against indolent and
aggressive B-cell non-Hodgkin’s lymphomas. Recombinant IFN and rIL-2 have
been variously included as adjuvant therapy and combined immune-therapy for
high risk and metastatic melanoma patients. Their use, efficacy and incidence of
adverse events are reported and discussed.
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